Trial Profile

PLATINUM China: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element) for the Treatment of a Single De Novo Coronary Artery Lesion

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Paclitaxel
Indications Coronary artery disease; Coronary artery restenosis
Focus Registrational; Therapeutic Use
Acronyms PLATINUM-China; PTChina
Sponsors Boston Scientific Corporation

Most Recent Events

27 Jan 2011 New trial record
26 Jan 2011 First patient enrolled, according to a Boston Scientific Corporation media release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com